on Biophytis (EPA:ALBPS)
Biophytis to Attend BIO International Convention in Boston
Biophytis SA, a biotechnology company focusing on treatments for age-related diseases, has announced its participation in the BIO International Convention. The event is set to take place from June 16 to 19, 2025, in Boston, USA. Edouard Bieth, the Chief Strategy Officer, will represent the company at the convention.
The primary objective for Biophytis is to showcase its latest developments, particularly regarding its drug candidate BIO101. This includes its Phase 2 OBA study focused on obesity treatment. The convention serves as an excellent platform to engage with international pharmaceutical companies for potential research or commercialization collaborations.
The BIO International Convention is a significant gathering in the biotech industry, bringing together 20,000 industry leaders globally. It unites various stakeholders, including pharmaceutical companies, biotech startups, and investors.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Biophytis news